Compare Enact Holdings Inc (ACT) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enact Holdings Inc vs Sana Biotechnology Inc — how do they compare? Enact Holdings Inc trades at $49.55 (market cap $6.75B), while Sana Biotechnology Inc trades at $3.77 (market cap $1.13B). The key difference: Enact Holdings Inc is far larger — about 6× Sana Biotechnology Inc's market cap, and Enact Holdings Inc pays a 1.95% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.
| ACT | SANA | |
|---|---|---|
Market Cap | $6.75B | $1.13B |
Sector | Technology | Health |
52-Week High | $49.12 | $5.92 |
52-Week Low | $34.93 | $2.68 |
Enterprise Value | $7.05B | $1.05B |
Dividend Yield | 1.95% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACT trades at $49.54, up 2.14% today, near the consensus price target of $49.00. The stock shows strong profitability with a net income margin of 54.51% and a P/E ratio of 10.36, indicating potential undervaluation. Recent Q2 2026 earnings beat estimates at $1.26 per share. Technical indicators signal a bullish trend, though RSI levels suggest overbought conditions. The company maintains stable dividends, with a $0.24 payout scheduled for September 2026.
Outlook is cautiously optimistic with solid fundamentals and analyst support, but risks include reliance on steady earnings growth and market volatility. The stock offers value with room for upside if earnings momentum continues, though overbought technicals may prompt short-term consolidation.
SANA Biotechnology trades at $3.77, up 4.43% today, with a bullish technical signal from moving averages and ADX indicators. The company reported a net loss of $244.17 million for 2025, with negative cash flow from operations, but analyst consensus is strongly positive with 82% buy ratings. Recent news highlights clinical data presentations and a $9.50 average price target from brokerages as of July 30, 2026.
The outlook hinges on clinical progress driving future profitability, but high cash burn and negative ROE pose significant risks. Upside potential exists if pipeline milestones are met, supported by institutional optimism, though investors face volatility from earnings misses and funding needs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Enact Holdings Inc
Enact Holdings is a leading private mortgage insurance provider in the U.S. It partners with lenders to offer credit enhancement and risk management solutions, helping more borrowers achieve and maintain homeownership.
Read more on ACT →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
